HARMONY BIOSCIENCES ANNOUNCES 2022 FUNDING RECIPIENTS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD PROGRAMS
PLYMOUTH MEETING, Pa., Sept. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ: HRMY), a pharmaceutical company dedicated todeveloping and commercializing innovative therapies for patients with rare neurological diseases, today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart and Progress at the Heart award programs.
- PLYMOUTH MEETING, Pa., Sept. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ: HRMY), a pharmaceutical company dedicated todeveloping and commercializing innovative therapies for patients with rare neurological diseases, today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart and Progress at the Heart award programs.
- This award funds innovative programs that address health disparities and inequities in rare neurological disease and sleep disorder communities.
- Combined with the Patients at the Heart awards, total funding for these two programs has now increased to $380,000 in over the last four years.
- "In recognition of World Narcolepsy Day, we are pleased to announce this year's recipients of the Patients at the Heart and Progress at the Heart award programs.